![Bart van Rhijn](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Bart van Rhijn
Director of Finance/CFO at NANOBIOTIX
Net worth: - $ as of 2024-06-29
Profile
Bart van Rhijn is currently the Chief Financial Officer at Nanobiotix SA since 2021.
Prior to this, he was the Chief Financial Officer at Servier Pharmaceuticals LLC from 2018 to 2021 and Head-Finance at Galderma International SAS from 2015 to 2018.
He has a graduate degree from the University of Leiden and an MBA from Olin Business School.
Known holdings in public companies
Company | Date | Number of shares | Valuation | Valuation date |
---|---|---|---|---|
NANOBIOTIX SA
-.--% | 2024-04-23 | 0 ( -.--% ) | - $ | 2024-06-29 |
Bart van Rhijn active positions
Companies | Position | Start |
---|---|---|
NANOBIOTIX | Director of Finance/CFO | 2021-05-31 |
Former positions of Bart van Rhijn
Companies | Position | End |
---|---|---|
Servier Pharmaceuticals LLC
![]() Servier Pharmaceuticals LLC Pharmaceuticals: MajorHealth Technology Part of Servier SAS, Servier Pharmaceuticals LLC is a privately held pharmaceutical company focused on oncology. The company, based in Boston, MA, was founded in 1954. Servier Pharmaceuticals is committed to innovation and improving the lives of patients, their families, and caregivers. The company invests in research and development to address the unmet needs of patients, particularly in the areas of oncology, cardiovascular diseases, cancers, diabetes, immuno-inflammatory, and neuro-psychiatric diseases. The company offers financial assistance to support patients, advocacy groups, and healthcare professionals. The company strives for transparency in clinical trials and research and development. Servier Pharmaceuticals aims to create a brighter future for all by providing life-saving treatments to a greater number of patients. The company actively seeks alliances, acquisitions, licensing deals, and partnerships to accelerate access to therapies. David K. Lee has been the CEO of the company since 2018. | Director of Finance/CFO | 2021-04-30 |
Galderma International SAS
![]() Galderma International SAS Pharmaceuticals: MajorHealth Technology Galderma SA develops and markets therapeutic and aesthetic solutions for dermatology. It provides medical dermatological solutions for acne, rosacea, psoriasis and other steroid-responsive dermatoses, onychomycosis, pigmentary disorders, skin cancer and medical aesthetic and corrective solutions for skin senescence. The company was founded in 1981 and is headquartered in Paris, France. | Corporate Officer/Principal | 2018-07-31 |
Training of Bart van Rhijn
Olin Business School | Masters Business Admin |
University of Leiden | Graduate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
Listed companies | 1 |
---|---|
NANOBIOTIX | Health Technology |
Private companies | 2 |
---|---|
Servier Pharmaceuticals LLC
![]() Servier Pharmaceuticals LLC Pharmaceuticals: MajorHealth Technology Part of Servier SAS, Servier Pharmaceuticals LLC is a privately held pharmaceutical company focused on oncology. The company, based in Boston, MA, was founded in 1954. Servier Pharmaceuticals is committed to innovation and improving the lives of patients, their families, and caregivers. The company invests in research and development to address the unmet needs of patients, particularly in the areas of oncology, cardiovascular diseases, cancers, diabetes, immuno-inflammatory, and neuro-psychiatric diseases. The company offers financial assistance to support patients, advocacy groups, and healthcare professionals. The company strives for transparency in clinical trials and research and development. Servier Pharmaceuticals aims to create a brighter future for all by providing life-saving treatments to a greater number of patients. The company actively seeks alliances, acquisitions, licensing deals, and partnerships to accelerate access to therapies. David K. Lee has been the CEO of the company since 2018. | Health Technology |
Galderma International SAS
![]() Galderma International SAS Pharmaceuticals: MajorHealth Technology Galderma SA develops and markets therapeutic and aesthetic solutions for dermatology. It provides medical dermatological solutions for acne, rosacea, psoriasis and other steroid-responsive dermatoses, onychomycosis, pigmentary disorders, skin cancer and medical aesthetic and corrective solutions for skin senescence. The company was founded in 1981 and is headquartered in Paris, France. | Health Technology |
- Stock Market
- Insiders
- Bart van Rhijn